1. Market Research
  2. > Nosocomial Infections - Pipeline Review, H2 2013

Nosocomial Infections - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 63 pages

Nosocomial Infections - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Nosocomial Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Nosocomial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nosocomial Infections. Nosocomial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Nosocomial Infections.
- A review of the Nosocomial Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Nosocomial Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Nosocomial Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Nosocomial Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Nosocomial Infections - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Nosocomial Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Nosocomial Infections 9
Nosocomial Infections Therapeutics under Development by Companies 11
Nosocomial Infections Therapeutics under Investigation by Universities/Institutes 13
Discovery and Pre-Clinical Stage Products 14
Comparative Analysis 14
Nosocomial Infections Therapeutics - Products under Development by Companies 15
Nosocomial Infections Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Nosocomial Infections Therapeutics Development 17
Pfizer Inc. 17
Paratek Pharmaceuticals, Inc. 18
Achaogen Inc. 19
Immupharma Plc 20
Priaxon AG 21
MAT Biopharma 22
Amura Holdings Ltd. 23
Integrated BioTherapeutics, Inc. 24
AIMM Therapeutics B.V. 25
SelectX Pharmaceuticals, Inc. 26
Cantab Biopharmaceuticals Limited 27
Agennix AG 28
Da Volterra 29
Nosocomial Infections - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
NVB-333 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
AM-112 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
MAR Program - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
IPP-203101 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
MAT-401 - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Hybrid Antibiotics - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Multivalent Staph Vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
ACHN-978 - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Clostridium Dificile Program - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
SXP-2523 - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
DAV-132 - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
DAV-148 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Enoyl Reductase Inhibitors - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
BVNC-1 - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
BVNC-2 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
Dap-3 Polymyxin Analogs - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
Monoclonal Antibody Therapeutics Program For Nosocomial Infections - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
TP-112 - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
TP-106 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
TP-107 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Nosocomial Infections Therapeutics - Drug Profile Updates 55
Nosocomial Infections Therapeutics - Dormant Products 56
Nosocomial Infections - Product Development Milestones 57
Featured News and Press Releases 57
Sep 07, 2012: Kalidex Pharma To Present Clinical Data On Next-generation Fluoroquinolone KPI-10 At ICAAC 2012 57
May 07, 2012: Integrated BioTherapeutics Receives $600,000 Phase I SBIR Grant For Novel Staph Vaccine 58
Mar 18, 2010: Achillion Announces Award Of NIH Grant To Study Unique Antibacterial Compound Series 58
Jan 28, 2010: Theravance Receives Response Letter From FDA For Telavancin NDA For The Treatment Of Nosocomial Pneumonia 59
Dec 14, 2009: Cubist Pharmaceuticals To Acquire Calixa Therapeutics 60
Nov 30, 2009: Theravance Announces The Completion Of Validation Phase Of Telavancin MAA By The EMEA 61
Oct 07, 2008: Novacta Therapeutics Achieves First Milestone From The Wellcome Trust's Strategic Translational Award For NVB302, A New Treatment For C. difficile Infection 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63



List of Tables

Number of Products Under Development for Nosocomial Infections, H2 2013 9
Products under Development for Nosocomial Infections - Comparative Analysis, H2 2013 10
Number of Products under Development by Companies, H2 2013 12
Number of Products under Investigation by Universities/Institutes, H2 2013 13
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 14
Products under Development by Companies, H2 2013 15
Products under Investigation by Universities/Institutes, H2 2013 16
Pfizer Inc., H2 2013 17
Paratek Pharmaceuticals, Inc., H2 2013 18
Achaogen Inc., H2 2013 19
Immupharma Plc, H2 2013 20
Priaxon AG, H2 2013 21
MAT Biopharma, H2 2013 22
Amura Holdings Ltd., H2 2013 23
Integrated BioTherapeutics, Inc., H2 2013 24
AIMM Therapeutics B.V., H2 2013 25
SelectX Pharmaceuticals, Inc., H2 2013 26
Cantab Biopharmaceuticals Limited, H2 2013 27
Agennix AG, H2 2013 28
Da Volterra, H2 2013 29
Assessment by Monotherapy Products, H2 2013 30
Assessment by Stage and Route of Administration, H2 2013 32
Assessment by Stage and Molecule Type, H2 2013 34
Nosocomial Infections Therapeutics - Drug Profile Updates 55
Nosocomial Infections Therapeutics - Dormant Products 56



List of Figures

Number of Products under Development for Nosocomial Infections, H2 2013 9
Products under Development for Nosocomial Infections - Comparative Analysis, H2 2013 10
Products under Development by Companies, H2 2013 11
Products under Investigation by Universities/Institutes, H2 2013 13
Discovery and Pre-Clinical Stage Products, H2 2013 14
Assessment by Monotherapy Products, H2 2013 30
Assessment by Route of Administration, H2 2013 31
Assessment by Stage and Route of Administration, H2 2013 32
Assessment by Molecule Type, H2 2013 33
Assessment by Stage and Molecule Type, H2 2013 34



Companies Mentioned

Pfizer Inc.
Paratek Pharmaceuticals, Inc.
Achaogen Inc.
Immupharma Plc
Priaxon AG
MAT Biopharma
Amura Holdings Ltd.
Integrated BioTherapeutics, Inc.
AIMM Therapeutics B.V.
SelectX Pharmaceuticals, Inc.
Cantab Biopharmaceuticals Limited
Agennix AG
Da Volterra

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.